These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 38756783)

  • 21. The contributions of vaccination and natural infection to the production of neutralizing antibodies against the SARS-CoV-2 prototype strain and variants.
    Xie H; Zhang J; Bai S; Lv M; Li J; Chen W; Suo L; Chen M; Zhao W; Zhou S; Wang J; Zhang A; Ma J; Wang F; Yan L; Li D; Wu J
    Int J Infect Dis; 2024 Jul; 144():107060. PubMed ID: 38670482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
    Zaeck LM; Tan NH; Rietdijk WJR; Geers D; Sablerolles RSG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Rugebregt S; Goorhuis A; Postma DF; Visser LG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; Haagmans BL; van Baarle D; Koopmans MPG; ; van der Kuy PHM; GeurtsvanKessel CH; de Vries RD
    Nat Commun; 2024 May; 15(1):4224. PubMed ID: 38762522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.
    Tunheim G; Fossum E; Robertson AH; Rø GØI; Chopra A; Vaage JT; Vikse EL; Kran AB; Magnus P; Trogstad L; Mjaaland S; Hungnes O; Lund-Johansen F
    BMC Infect Dis; 2024 Aug; 24(1):841. PubMed ID: 39164637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
    Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
    Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
    Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G
    Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
    Faraone JN; Wang X; Qu P; Zheng YM; Vincent E; Xu H; Liu SL
    J Med Virol; 2024 Mar; 96(3):e29520. PubMed ID: 38528837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individuals carrying the HLA-B*15 allele exhibit favorable responses to COVID-19 vaccines but are more susceptible to Omicron BA.5.2 and XBB.1.16 infection.
    Meng L; Pan Y; Liu Y; He R; Sun Y; Wang C; Fei L; Zhu A; Wang Z; An Y; Wu Y; Diao B; Chen Y
    Front Immunol; 2024; 15():1440819. PubMed ID: 39257586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
    Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
    Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients.
    Overheu O; Lendowski S; Quast DR; Kühn D; Vidal Blanco E; Kraeft AL; Steinmann E; Kourti E; Lugnier C; Steinmann J; Reinacher-Schick A; Pfaender S
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10633-10644. PubMed ID: 37300723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan.
    Matsumoto N; Sasaki A; Kadowaki T; Mitsuhashi T; Takao S; Yorifuji T
    Vaccine; 2024 Aug; 42(21):126156. PubMed ID: 39088986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.
    Rivera-Pérez D; Méndez C; Diethelm-Varela B; Melo-González F; Vázquez Y; Meng X; Xin Q; Fasce RA; Fernández J; Mora J; Ramirez E; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Grifoni A; Weiskopf D; Sette A; Astudillo P; Le Corre N; Abarca K; Perret C; González PA; Soto JA; Bueno SM; Kalergis AM
    Front Immunol; 2024; 15():1372193. PubMed ID: 38812507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PMMA dialyzers modulate both humoral and cell-mediate immune response to anti-COVID-19 vaccine (BNT162b2) in a cohort of chronic hemodialyzed patients.
    Castellano G; Netti GS; Cantaluppi V; Losappio V; Spadaccino F; Ranieri E; Marengo M; Borzumati M; Alfieri C; Stallone G
    Sci Rep; 2024 May; 14(1):12217. PubMed ID: 38806543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
    Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
    Springer DN; Camp JV; Aberle SW; Deutsch J; Lammel O; Weseslindtner L; Stiasny K; Aberle JH
    J Med Virol; 2024 Jul; 96(7):e29801. PubMed ID: 38988204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
    Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
    Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the induction of humoral and cellular immunity by third vaccination for SARS-CoV-2.
    Murayama G; Kusaoi M; Horiuchi Y; Tabe Y; Naito T; Ito S; Yamaji K; Tamura N
    J Infect Chemother; 2024 Oct; 30(10):1021-1027. PubMed ID: 38570139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.
    Wietschel KA; Fechtner K; Antileo E; Abdurrahman G; Drechsler CA; Makuvise MK; Rose R; Voß M; Krumbholz A; Michalik S; Weiss S; Ulm L; Franikowski P; Fickenscher H; Bröker BM; Raafat D; Holtfreter S
    Front Immunol; 2024; 15():1382911. PubMed ID: 38807606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower Humoral and Cellular Immunity Following Asymptomatic SARS-CoV-2 Infection Compared to Symptomatic Infection in Education (The ACE Cohort).
    Hopkins G; Gomez N; Tucis D; Bartlett L; Steers G; Burns E; Brown M; Harvey-Cowlishaw T; Santos R; Lauder SN; Scurr M; Capitani L; Burnell S; Rees T; Smart K; Somerville M; Gallimore A; Perera M; Potts M; Metaxaki M; Krishna B; Jackson H; Tighe P; Onion D; Godkin A; Wills M; Fairclough L
    J Clin Immunol; 2024 Jun; 44(6):147. PubMed ID: 38856804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.